Neo Ivy Capital Management Acquires New Holdings in Jazz Pharmaceuticals PLC $JAZZ

Neo Ivy Capital Management bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 13,930 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,836,000.

A number of other hedge funds have also added to or reduced their stakes in JAZZ. EverSource Wealth Advisors LLC raised its stake in Jazz Pharmaceuticals by 9.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 81 shares during the last quarter. Tectonic Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 1.5% in the 3rd quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after buying an additional 82 shares during the last quarter. Fairbanks Capital Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 0.4% in the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after buying an additional 94 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Jazz Pharmaceuticals by 3.5% in the third quarter. Blue Trust Inc. now owns 3,261 shares of the specialty pharmaceutical company’s stock worth $430,000 after acquiring an additional 109 shares during the period. Finally, Arkadios Wealth Advisors increased its position in Jazz Pharmaceuticals by 0.9% during the third quarter. Arkadios Wealth Advisors now owns 13,948 shares of the specialty pharmaceutical company’s stock valued at $1,838,000 after acquiring an additional 123 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Down 0.9%

Shares of JAZZ stock opened at $182.01 on Friday. The company has a market capitalization of $11.20 billion, a price-to-earnings ratio of -30.49, a PEG ratio of 0.36 and a beta of 0.22. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $198.00. The company’s fifty day moving average price is $171.11 and its 200-day moving average price is $153.84. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the firm posted $6.51 EPS. Jazz Pharmaceuticals’s quarterly revenue was up 8.1% compared to the same quarter last year. Sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,253 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $194.11, for a total value of $243,219.83. Following the completion of the transaction, the chief accounting officer owned 10,352 shares of the company’s stock, valued at $2,009,426.72. This represents a 10.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Norbert G. Riedel sold 3,415 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $192.00, for a total value of $655,680.00. Following the sale, the director owned 7,024 shares of the company’s stock, valued at $1,348,608. This represents a 32.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 68,966 shares of company stock valued at $13,181,406 over the last three months. Insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on JAZZ shares. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Royal Bank Of Canada increased their price objective on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Robert W. Baird lifted their price target on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $214.57.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.